# TB-500 FAQ: Safety, Side Effects, BPC-157 Comparison, and Status

> TB-500 FAQ: side effects and safety signals, the thymosin beta-4 fragment versus BPC-157, the steroid question, muscle and tendon evidence, and regulatory standing — cited.

Direct answers first, citations after. Where the figure is human-unproven for the fragment, the answer says so.

## What is TB-500?

TB-500 is the synthetic, N-acetylated heptapeptide Ac-LKKTETQ — residues 17-23, the actin-binding motif, of the 43-amino-acid protein thymosin beta-4. Its molecular weight is 889.02 Da. Most published efficacy research is on the full-length protein, not the 7-mer [5][1].

## What does TB-500 stand for and what does TB stand for in TB-500?

TB references thymosin beta — specifically thymosin beta-4. TB-500 is the research and veterinary designation for the synthetic Ac-LKKTETQ fragment of that protein. The name marks the fragment's parentage, not a separate molecule from thymosin beta-4's actin-binding region [5].

## What is TB-500 used for in research?

In the literature, thymosin beta-4 and its LKKTETQ region are studied for tissue repair, cell migration, angiogenesis, anti-inflammatory and anti-fibrotic effects, and cardiac, corneal and neurological injury models [5][9][7]. The work is predominantly in animals and in vitro; it describes research findings, not approved uses of the fragment.

## Is TB-500 a Steroid?

No. TB-500 is a peptide — a short chain of seven amino acids (Ac-LKKTETQ) from thymosin beta-4 — not a steroid. Steroids are lipid-based molecules built on a four-ring carbon skeleton; TB-500 works through actin binding and cell-migration biology, a completely different mechanism [1].

## Reported Safety Signals and Side-Effect Considerations

No human side-effect profile is established for the TB-500 heptapeptide. The principal documented signal is the tumor/angiogenesis theoretical concern: thymosin beta-4 is overexpressed in several cancers and implicated in metastasis, so its pro-migratory, pro-angiogenic activity is an oncologic caution rather than a demonstrated outcome of the fragment in humans [13]. Full-length thymosin beta-4 was well tolerated to 1260 mg intravenously in a Phase 1 study, but that is the protein, not the 7-mer [6]. The other recurring concern is material quality — identity, purity and correct sequence are not guaranteed in unregulated research-grade supply, which also complicates interpreting anecdotal reports [13].

## What are the side effects of TB-500?

No human side-effect profile is established for the fragment. The main documented signals are the tumor/angiogenesis theoretical concern and the absence of controlled human safety data [13]. Full-length thymosin beta-4 was well tolerated to 1260 mg intravenously in a Phase 1 study, but that is the protein, not the TB-500 heptapeptide [6].

## Does TB-500 cause cancer or promote tumor growth?

Thymosin beta-4 is overexpressed in several cancers and implicated in metastasis and tumor angiogenesis, so its pro-migratory, pro-angiogenic activity is a theoretical oncologic concern [13]. This is a safety signal, not a demonstrated outcome of the TB-500 fragment in humans, for whom controlled data do not exist. The concern derives largely from full-length thymosin beta-4 biology.

## Is TB-500 safe for long-term use?

Long-term safety of the TB-500 fragment in humans is unknown — there are no controlled long-term human trials [13]. The tumor/angiogenesis signal and unregulated material quality are the key open concerns. TB-500 is a research compound, not a human therapy, and no validated long-term safety data support extended administration of the heptapeptide.

## How TB-500 Differs From BPC-157 in the Research

TB-500 and BPC-157 are often discussed together but act through different biology. TB-500 is the Ac-LKKTETQ fragment of thymosin beta-4, working through actin binding, cell migration and angiogenesis [1][7]. BPC-157 is a separate pentadecapeptide studied in tissue-repair models. What they share is regulatory standing: the 2026 Sports Medicine review groups both among unapproved musculoskeletal peptides with favorable animal outcomes but scarce human safety data and potential for serious harm [13]. Neither is an approved human therapy.

## What is the difference between TB-500 and BPC-157?

Both are unapproved peptides studied for tissue repair, but TB-500 is the Ac-LKKTETQ fragment of thymosin beta-4 acting through actin and migration biology [1], while BPC-157 is a distinct pentadecapeptide. A 2026 Sports Medicine review groups both among unapproved musculoskeletal peptides with favorable animal outcomes but scarce human safety data [13].

## Does TB-500 work for muscle tears and recovery from exercise?

Animal data show thymosin beta-4 acts as a myoblast chemoattractant and increased regenerating fibers in dystrophin-deficient (mdx) mice — but the same study found no gain in muscle strength. A 2026 Sports Medicine review lists TB-500 among unapproved peptides with favorable animal outcomes and scarce human safety and efficacy data [13]. There is no controlled human evidence for exercise recovery with the fragment.

## Can TB-500 help with tendon injuries and ligament repair?

Thymosin beta-4 enhanced healing of a medial collateral ligament injury in a rat model — one of the few direct connective-tissue findings behind the athletic-recovery rationale [5]. Human evidence is lacking, and the 2026 Sports Medicine review keeps TB-500 in the unapproved column with scarce human data [13]. The connective-tissue case is animal-only at present.

## How long does it take for TB-500 to work for injury healing?

No validated human healing timeline exists. In a rat full-thickness wound model, thymosin beta-4 raised re-epithelialization by 42% at four days and up to 61% at seven days versus saline [3]. That is an animal timescale from the full-length protein, not a human dosing schedule for the fragment, and it should not be read as one.

---

Legit TB-500 runs the thymosin beta-4 literature like a status check: the seven-mer marked present, the full-length protein where the data actually live marked separately, the human-evidence column returning zero, and FDA's standing quoted straight — a console for verifying claims, not a clinic, a pharmacy, or a place anything is sold.